TY  - CONF
AU  - Spasojević-Tišma, V.
AU  - Jeremić, M.
AU  - Pejić, Snežana
AU  - Drakulić, Dunja R.
AU  - Stanković, S.
AU  - Košutić, D.
AU  - Todorović, Ana
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/12865
AB  - BACKGROUND-AIM Differentiated thyroid cancer (DTC) is the most rapidly diagnosed cancer worldwide and the most frequent endocrinemalignancy, comprised of differentiated subtypes, specifically papillary and follicular thyroid cancer. Thyroidectomyis currently the preferred treatment for DTC. However, adjuvant therapy in the form of radioactive iodine (131I) is oftenadministered to reduce the risk of tumor recurrence and to facilitate future cancer surveillance. As 131I treatmentadditionally might upregulate oxidative stress regularly observed in thyroid cancer patients, the aim of our study wasto investigate the alterations in the levels of glutathione (GSH), superoxide anion (O2-), nitric oxide (NO) and activityof superoxide dismutase (SOD) in blood of DTC patients treated with 131I. METHODS All investigated parameters were determined with well-established spectrophotometric methods in blood samples ofthyroidectomized DTC patients obtained 0 (before), 3, 7 and 30 days after the 131I treatment. The treatment was orallyadministered once in the dose of 3.7 GBq. RESULTS Our results showed that, compared to the values before the therapy, SOD activity was significantly increased on the3th and 30th day after the 131I treatment alongwith the levels of GSH on 7th day. Other investigated oxidative stressindicators were unchanged. According to obtained data, in the blood of thyroidectomized DTC patients during the first30 days after the therapy, increased antioxidative capacity, reflected through upregulated SOD activity and GSH levels,might be sufficient to prevent the increase of O2- and NO and, in general, suppress the oxidative stress. CONCLUSIONS Our findings provide a better insight into individual antioxidant parameters fluctuations, thus contribute to a betterunderstanding of the redox mechanisms critical for 131I treatment outcomes, since an increase in the oxidative stressin the early stages of therapy can affect later health concerns and may represent a potential risk factor for cancerprogression in DTC patients.
PB  - Berlin ; Boston : Walter de Gruyter
C3  - Clinical chemistry and laboratory medicine
T1  - Oxidative Stress in Differentiated Thyroid Cancer Patients After Radioiodine Treatment
VL  - 61
IS  - Special Supplement
SP  - S1416
EP  - S1416
DO  - 10.1515/cclm-2023-7051
ER  - 

@conference{
author = "Spasojević-Tišma, V. and Jeremić, M. and Pejić, Snežana and Drakulić, Dunja R. and Stanković, S. and Košutić, D. and Todorović, Ana",
year = "2023",
abstract = "BACKGROUND-AIM Differentiated thyroid cancer (DTC) is the most rapidly diagnosed cancer worldwide and the most frequent endocrinemalignancy, comprised of differentiated subtypes, specifically papillary and follicular thyroid cancer. Thyroidectomyis currently the preferred treatment for DTC. However, adjuvant therapy in the form of radioactive iodine (131I) is oftenadministered to reduce the risk of tumor recurrence and to facilitate future cancer surveillance. As 131I treatmentadditionally might upregulate oxidative stress regularly observed in thyroid cancer patients, the aim of our study wasto investigate the alterations in the levels of glutathione (GSH), superoxide anion (O2-), nitric oxide (NO) and activityof superoxide dismutase (SOD) in blood of DTC patients treated with 131I. METHODS All investigated parameters were determined with well-established spectrophotometric methods in blood samples ofthyroidectomized DTC patients obtained 0 (before), 3, 7 and 30 days after the 131I treatment. The treatment was orallyadministered once in the dose of 3.7 GBq. RESULTS Our results showed that, compared to the values before the therapy, SOD activity was significantly increased on the3th and 30th day after the 131I treatment alongwith the levels of GSH on 7th day. Other investigated oxidative stressindicators were unchanged. According to obtained data, in the blood of thyroidectomized DTC patients during the first30 days after the therapy, increased antioxidative capacity, reflected through upregulated SOD activity and GSH levels,might be sufficient to prevent the increase of O2- and NO and, in general, suppress the oxidative stress. CONCLUSIONS Our findings provide a better insight into individual antioxidant parameters fluctuations, thus contribute to a betterunderstanding of the redox mechanisms critical for 131I treatment outcomes, since an increase in the oxidative stressin the early stages of therapy can affect later health concerns and may represent a potential risk factor for cancerprogression in DTC patients.",
publisher = "Berlin ; Boston : Walter de Gruyter",
journal = "Clinical chemistry and laboratory medicine",
title = "Oxidative Stress in Differentiated Thyroid Cancer Patients After Radioiodine Treatment",
volume = "61",
number = "Special Supplement",
pages = "S1416-S1416",
doi = "10.1515/cclm-2023-7051"
}

Spasojević-Tišma, V., Jeremić, M., Pejić, S., Drakulić, D. R., Stanković, S., Košutić, D.,& Todorović, A.. (2023). Oxidative Stress in Differentiated Thyroid Cancer Patients After Radioiodine Treatment. in Clinical chemistry and laboratory medicine
Berlin ; Boston : Walter de Gruyter., 61(Special Supplement), S1416-S1416.
https://doi.org/10.1515/cclm-2023-7051

Spasojević-Tišma V, Jeremić M, Pejić S, Drakulić DR, Stanković S, Košutić D, Todorović A. Oxidative Stress in Differentiated Thyroid Cancer Patients After Radioiodine Treatment. in Clinical chemistry and laboratory medicine. 2023;61(Special Supplement):S1416-S1416.
doi:10.1515/cclm-2023-7051 .

Spasojević-Tišma, V., Jeremić, M., Pejić, Snežana, Drakulić, Dunja R., Stanković, S., Košutić, D., Todorović, Ana, "Oxidative Stress in Differentiated Thyroid Cancer Patients After Radioiodine Treatment" in Clinical chemistry and laboratory medicine, 61, no. Special Supplement (2023):S1416-S1416,
https://doi.org/10.1515/cclm-2023-7051 . .